149 related articles for article (PubMed ID: 16506988)
1. Development of a preliminary framework for informing the risk analysis and risk management of nanoparticles.
Morgan K
Risk Anal; 2005 Dec; 25(6):1621-35. PubMed ID: 16506988
[TBL] [Abstract][Full Text] [Related]
2. Framework for use of toxicity screening tools in context-based decision-making.
Doull J; Borzelleca JF; Becker R; Daston G; DeSesso J; Fan A; Fenner-Crisp P; Holsapple M; Holson J; Craig Llewellyn G; MacGregor J; Seed J; Walls I; Woo YT; Olin S
Food Chem Toxicol; 2007 May; 45(5):759-96. PubMed ID: 17215066
[TBL] [Abstract][Full Text] [Related]
3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
4. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology.
Oberdörster G
J Intern Med; 2010 Jan; 267(1):89-105. PubMed ID: 20059646
[TBL] [Abstract][Full Text] [Related]
5. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles.
Tsuji JS; Maynard AD; Howard PC; James JT; Lam CW; Warheit DB; Santamaria AB
Toxicol Sci; 2006 Jan; 89(1):42-50. PubMed ID: 16177233
[TBL] [Abstract][Full Text] [Related]
6. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
7. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
8. Nanotechnology: the next big thing, or much ado about nothing?
Maynard AD
Ann Occup Hyg; 2007 Jan; 51(1):1-12. PubMed ID: 17041243
[TBL] [Abstract][Full Text] [Related]
9. [Research strategy for evaluation methods of the manufactured nanomaterials in NIHS and importance of the chronic health effects studies].
Hirose A; Nishimura T; Kanno J
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2009; (127):15-25. PubMed ID: 20306702
[TBL] [Abstract][Full Text] [Related]
10. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
[TBL] [Abstract][Full Text] [Related]
11. Development of a base set of toxicity tests using ultrafine TiO2 particles as a component of nanoparticle risk management.
Warheit DB; Hoke RA; Finlay C; Donner EM; Reed KL; Sayes CM
Toxicol Lett; 2007 Jul; 171(3):99-110. PubMed ID: 17566673
[TBL] [Abstract][Full Text] [Related]
12. Health effects related to nanoparticle exposures: environmental, health and safety considerations for assessing hazards and risks.
Warheit DB; Sayes CM; Reed KL; Swain KA
Pharmacol Ther; 2008 Oct; 120(1):35-42. PubMed ID: 18703086
[TBL] [Abstract][Full Text] [Related]
13. Risk analysis and protection measures in a carbon nanofiber manufacturing enterprise: an exploratory investigation.
Genaidy A; Sequeira R; Rinder M; A-Rehim A
Sci Total Environ; 2009 Nov; 407(22):5825-38. PubMed ID: 19712959
[TBL] [Abstract][Full Text] [Related]
14. Nanomaterials and lung toxicity: interactions with airways cells and relevance for occupational health risk assessment.
Bergamaschi E; Bussolati O; Magrini A; Bottini M; Migliore L; Bellucci S; Iavicoli I; Bergamaschi A
Int J Immunopathol Pharmacol; 2006; 19(4 Suppl):3-10. PubMed ID: 17291399
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnological medical devices and nanopharmaceuticals: the European regulatory framework and research needs.
Rickerby DG
J Nanosci Nanotechnol; 2007 Dec; 7(12):4618-25. PubMed ID: 18283854
[TBL] [Abstract][Full Text] [Related]
16. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety.
Nohynek GJ; Lademann J; Ribaud C; Roberts MS
Crit Rev Toxicol; 2007 Mar; 37(3):251-77. PubMed ID: 17453934
[TBL] [Abstract][Full Text] [Related]
17. [Health effects of engineered nanomaterials].
Pietroiusti A; Magrini A; Bergamaschi A; Iavicoli I
G Ital Med Lav Ergon; 2010; 32(4 Suppl):287-9. PubMed ID: 21438282
[TBL] [Abstract][Full Text] [Related]
18. Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials.
Som C; Nowack B; Krug HF; Wick P
Acc Chem Res; 2013 Mar; 46(3):863-72. PubMed ID: 23110540
[TBL] [Abstract][Full Text] [Related]
19. Do nanoparticles present ecotoxicological risks for the health of the aquatic environment?
Moore MN
Environ Int; 2006 Dec; 32(8):967-76. PubMed ID: 16859745
[TBL] [Abstract][Full Text] [Related]
20. The importance of life cycle concepts for the development of safe nanoproducts.
Som C; Berges M; Chaudhry Q; Dusinska M; Fernandes TF; Olsen SI; Nowack B
Toxicology; 2010 Mar; 269(2-3):160-9. PubMed ID: 20025922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
